Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01286909

Acronym

LaFlavon

Enrollment

Registered

2011-01-31

Start date

2011-01-31

Completion date

2011-06-30

Last updated

2011-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Disease

Keywords

Metabolic

Brief summary

A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).

Interventions

DIETARY_SUPPLEMENTLaFlavon

two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Men and Women with Metabolic Syndrome 2. Elevated Triglycerides (\> 150) 3. Low High-Density Lipoprotein (HDL) (\< 35) 4. Willingness to take study nutritional supplement once a day for 3 months

Exclusion criteria

1. Women who are pregnant, nursing, or who intend pregnancy during the period of treatment 2. Known milk, soy or whey allergy

Design outcomes

Primary

Measure	Time frame
Increase in High-Density Lipoprotein (HDL)	Change from Baseline in High-Density Lipoprotein (HDL) at 3 months

Secondary

Measure	Time frame
changes of liver enzymes	Baseline and 3 months

Countries

Lebanon

Contacts

Primary ContactDr. Akram Echtay, M.D.

+9613856323

Backup ContactSanan Sdepanian

sanan_sdepanian@yahoo.com+9617098618

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026